Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation
Background/purposeDespite advances in chronic lymphocytic leukemia treatment, effective therapies for cases with Richter’s transformation (RT) are urgently needed. This study aimed to investigate the use of chimeric antigen receptor (CAR)-T cell infusion for RT.MethodsThis study included RT patients...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1591360/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849722922035314688 |
|---|---|
| author | Shaomei Feng Peihao Zheng Haidi Liu Meiling Sun Yuelu Guo Lixia Ma Rui Liu Zhonghua Fu Fan Yang Xiaoyan Ke Kai Hu |
| author_facet | Shaomei Feng Peihao Zheng Haidi Liu Meiling Sun Yuelu Guo Lixia Ma Rui Liu Zhonghua Fu Fan Yang Xiaoyan Ke Kai Hu |
| author_sort | Shaomei Feng |
| collection | DOAJ |
| description | Background/purposeDespite advances in chronic lymphocytic leukemia treatment, effective therapies for cases with Richter’s transformation (RT) are urgently needed. This study aimed to investigate the use of chimeric antigen receptor (CAR)-T cell infusion for RT.MethodsThis study included RT patients at Beijing Boren Hospital between February 2020 and February 2023. Complete response (CR), partial response (PR), overall response rate (ORR), overall survival (OS), progression free survival (PFS), and adverse events were analyzed.ResultsData from 16 patients with RT who underwent CAR-T cell therapy [62.5% (10/16) males and a median age of 59 years (range: 42–69 years)] were collected. The 3-month CR rate was 56.3% (9/16), with an ORR of 68.8% (11/16). Median follow-up was 19.1 months (4.37-42.48m), the 1-year OS/PFS were 75.0%/68.8%, and the 2-year OS/PFS were 67.5%/61.1%. Among 11 patients with CR (n=9) and PR (n=2), 1 CR case died of an acute coronary event, 10 patients had no recurrence or progression at a median follow-up of 24.6 months. Five patients who did not respond to CAR-T cell therapy had a median OS of only 6.44 months. Univariate logistic regression analysis showed ECOG score [odds ratio (OR)=0.025, P=0.016] were independently associated with ORR. ECOG (OR=40, P=0.016) were independently associated with OS. The presence of an extramedullary mass larger than 5cm did not show statistical significance for overall survival (OS), although the P value was close to 0.05 (OR=15, P=0.051).ConclusionsCAR-T cell therapy showed potential as a treatment for RT. ECOG score may be independently associated with ORR and OS. RT patients may experience prolonged remission and achieve long-term disease control if they attain remission through chimeric antigen receptor T-cell therapy. |
| format | Article |
| id | doaj-art-2616b4f024c64ecea1fe2b3b26b8bed9 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-2616b4f024c64ecea1fe2b3b26b8bed92025-08-20T03:11:11ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15913601591360Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformationShaomei Feng0Peihao Zheng1Haidi Liu2Meiling Sun3Yuelu Guo4Lixia Ma5Rui Liu6Zhonghua Fu7Fan Yang8Xiaoyan Ke9Kai Hu10Department of Myeloma and Lymphoma, Beijing GoBroad Boren Hospital, Beijing, ChinaDepartment of Myeloma and Lymphoma, Beijing GoBroad Boren Hospital, Beijing, ChinaDepartment of Myeloma and Lymphoma, Beijing GoBroad Boren Hospital, Beijing, ChinaDepartment of Myeloma and Lymphoma, Beijing GoBroad Boren Hospital, Beijing, ChinaDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, ChinaDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, ChinaDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, ChinaDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, ChinaDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, ChinaDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, ChinaDepartment of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, ChinaBackground/purposeDespite advances in chronic lymphocytic leukemia treatment, effective therapies for cases with Richter’s transformation (RT) are urgently needed. This study aimed to investigate the use of chimeric antigen receptor (CAR)-T cell infusion for RT.MethodsThis study included RT patients at Beijing Boren Hospital between February 2020 and February 2023. Complete response (CR), partial response (PR), overall response rate (ORR), overall survival (OS), progression free survival (PFS), and adverse events were analyzed.ResultsData from 16 patients with RT who underwent CAR-T cell therapy [62.5% (10/16) males and a median age of 59 years (range: 42–69 years)] were collected. The 3-month CR rate was 56.3% (9/16), with an ORR of 68.8% (11/16). Median follow-up was 19.1 months (4.37-42.48m), the 1-year OS/PFS were 75.0%/68.8%, and the 2-year OS/PFS were 67.5%/61.1%. Among 11 patients with CR (n=9) and PR (n=2), 1 CR case died of an acute coronary event, 10 patients had no recurrence or progression at a median follow-up of 24.6 months. Five patients who did not respond to CAR-T cell therapy had a median OS of only 6.44 months. Univariate logistic regression analysis showed ECOG score [odds ratio (OR)=0.025, P=0.016] were independently associated with ORR. ECOG (OR=40, P=0.016) were independently associated with OS. The presence of an extramedullary mass larger than 5cm did not show statistical significance for overall survival (OS), although the P value was close to 0.05 (OR=15, P=0.051).ConclusionsCAR-T cell therapy showed potential as a treatment for RT. ECOG score may be independently associated with ORR and OS. RT patients may experience prolonged remission and achieve long-term disease control if they attain remission through chimeric antigen receptor T-cell therapy.https://www.frontiersin.org/articles/10.3389/fonc.2025.1591360/fullCAR-T cell therapyleukemiadisease progressionsurvival analysisRichter’s transformationB-NHL |
| spellingShingle | Shaomei Feng Peihao Zheng Haidi Liu Meiling Sun Yuelu Guo Lixia Ma Rui Liu Zhonghua Fu Fan Yang Xiaoyan Ke Kai Hu Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation Frontiers in Oncology CAR-T cell therapy leukemia disease progression survival analysis Richter’s transformation B-NHL |
| title | Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation |
| title_full | Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation |
| title_fullStr | Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation |
| title_full_unstemmed | Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation |
| title_short | Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation |
| title_sort | chimeric antigen receptor car t cell therapy treatment richter s transformation |
| topic | CAR-T cell therapy leukemia disease progression survival analysis Richter’s transformation B-NHL |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1591360/full |
| work_keys_str_mv | AT shaomeifeng chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT peihaozheng chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT haidiliu chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT meilingsun chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT yueluguo chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT lixiama chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT ruiliu chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT zhonghuafu chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT fanyang chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT xiaoyanke chimericantigenreceptorcartcelltherapytreatmentrichterstransformation AT kaihu chimericantigenreceptorcartcelltherapytreatmentrichterstransformation |